IL159048D0 - Sustained release formulation - Google Patents

Sustained release formulation

Info

Publication number
IL159048D0
IL159048D0 IL15904802A IL15904802A IL159048D0 IL 159048 D0 IL159048 D0 IL 159048D0 IL 15904802 A IL15904802 A IL 15904802A IL 15904802 A IL15904802 A IL 15904802A IL 159048 D0 IL159048 D0 IL 159048D0
Authority
IL
Israel
Prior art keywords
sustained release
release formulation
formulation
sustained
Prior art date
Application number
IL15904802A
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30027501P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to US10/176,961 priority patent/US7318931B2/en
Priority to PCT/US2002/019597 priority patent/WO2003000282A1/en
Publication of IL159048D0 publication Critical patent/IL159048D0/en

Links

IL15904802A 2001-06-21 2002-06-21 Sustained release formulation IL159048D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US30027501P true 2001-06-21 2001-06-21
US10/176,961 US7318931B2 (en) 2001-06-21 2002-06-21 Sustained release formulation
PCT/US2002/019597 WO2003000282A1 (en) 2001-06-21 2002-06-21 Sustained release formulation

Publications (1)

Publication Number Publication Date
IL159048D0 true IL159048D0 (en) 2004-05-12

Family

ID=26872798

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15904802A IL159048D0 (en) 2001-06-21 2002-06-21 Sustained release formulation

Country Status (10)

Country Link
US (2) US7318931B2 (en)
EP (1) EP1397155B1 (en)
JP (2) JP4460892B2 (en)
AU (1) AU2002320122B2 (en)
CA (1) CA2448218C (en)
DK (1) DK1397155T3 (en)
ES (1) ES2554106T3 (en)
IL (1) IL159048D0 (en)
PT (1) PT1397155E (en)
WO (1) WO2003000282A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2496687A1 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
DE10312346A1 (en) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Controlled release system
BRPI0408925A (en) * 2003-03-31 2006-04-04 Alza Corp single phase non-aqueous vehicles and formulations using such vehicles
CN100364499C (en) * 2003-05-01 2008-01-30 日本株式会社Ltt生物医药 Zinc-containing sustained-release composition, its preparation, and method for producing the same
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005067960A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EP3103477A1 (en) * 2004-09-17 2016-12-14 Durect Corporation Sustained local anesthetic composition containing saib
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1912676A2 (en) * 2005-07-28 2008-04-23 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate
US7456251B2 (en) * 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
ES2351527T3 (en) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Flow modulator in two pieces with internal conduit for an osmotic delivery system.
WO2008066642A2 (en) 2006-11-03 2008-06-05 Durect Corporation Transdermal delivery systems comprising bupivacaine
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
KR20100016142A (en) * 2007-04-03 2010-02-12 트라이머리스, 인코퍼레이티드 Novel formulations for delivery of antiviral peptide therapeutics
CN105688191A (en) 2007-04-23 2016-06-22 精达制药公司 Suspension formulations of insulinotropic peptides and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0817697A2 (en) * 2007-09-25 2015-04-07 Trimeris Inc Synthesis method of a peptide, set of peptide fragments, and, peptide
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
AU2009212367B2 (en) * 2008-02-08 2013-08-01 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009129101A1 (en) 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
BRPI0921320A2 (en) * 2008-11-28 2018-05-22 Abbott Lab stable antibody compositions and methods for stabilizing them
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
CA2792771A1 (en) * 2010-03-12 2011-09-15 Surmodics, Inc. Injectable drug delivery system
CN107441493A (en) 2010-08-18 2017-12-08 德玛医药 Compositions And Methods To Improve The Therapeutic Benefit Of Suboptimally Administered Chemical Compounds Including Substituted Hexitols Such As Dianhydrogalactitol And Diacetyldianhydrogalactitol
TWI606840B (en) 2010-11-11 2017-12-01 Abbvie Biotechnology Ltd Having a high concentration of anti-promotional -TNFα liquid formulations of antibody
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX354988B (en) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Antibody formulations and methods.
AU2013209394A1 (en) 2012-01-20 2014-08-28 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6476540B2 (en) * 2013-10-08 2019-03-06 株式会社リコー Display device, display system, and program
WO2015058868A1 (en) 2013-10-25 2015-04-30 Pangaea Biotech, S.L. Compositions and methods for the treatment of cancer
TW201618783A (en) 2014-08-07 2016-06-01 艾森塔製藥公司 With Bruton (Bruton) 's tyrosine kinase (BTK) BTK occupied and re-synthesis rate based on the treatment of cancer, immune and autoimmune diseases and inflammatory diseases of the method
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456433A (en) * 1973-06-25 1976-11-24 Quaker Oats Co Semi-moist cat food
US4016273A (en) * 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
DE2916711A1 (en) * 1979-04-25 1980-11-06 Behringwerke Ag Blood clotting factors and methods for their production
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
JPH0482040B2 (en) 1986-05-02 1992-12-25 Kao Corp
WO1989003671A1 (en) 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0223866A (en) 1988-07-11 1990-01-26 Kikkoman Corp Stabilization of sucrose phosphorylase
FR2634121B1 (en) 1988-07-13 1992-05-07 Imedex Process for the preparation of collagen microparticles and products obtained
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4975271A (en) * 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5114929A (en) 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
SE465950B (en) 1989-10-23 1991-11-25 Medinvent Sa Combination of an aggregate particulate, crystalline or freeze-dried laekemedel with a pseudoplastic gel foer preparation of an injectable preparation and foerfarande foer its framstaellning
US5133981A (en) * 1989-11-17 1992-07-28 Atrix Laboratories, Inc. Purification of benzophenanthridine alkaloids extracts from alkaloid extracts
ZA9108526B (en) * 1990-10-30 1992-08-26 Alza Corp Drug delivery system and method
JPH04271785A (en) 1991-02-28 1992-09-28 Kao Corp Enzymic solid pharmaceutical and its production
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0831786A2 (en) 1995-06-07 1998-04-01 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
AT195652T (en) 1992-12-02 2000-09-15 Alkermes Inc Growth hormone-containing microsphere controlled-release
EP0831787B1 (en) 1995-06-07 2001-08-22 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
CZ296649B6 (en) 1993-02-23 2006-05-17 Genentech, Inc. Process for preparing stabilized polypeptide composition comprising stabilizing polypeptide against denaturation when treated with organic solvents, preparation of the polypeptide and composition for controlled release of polypeptide
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
JP3125610B2 (en) 1993-12-24 2001-01-22 和光純薬工業株式会社 Stabilization Act of L- methionine γ- lyase
DE69508985D1 (en) * 1994-02-21 1999-05-20 Takeda Chemical Industries Ltd Polyester Matrix for a pharmaceutical composition having sustained release
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
CA2582666C (en) * 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
JP4330175B2 (en) 1995-06-07 2009-09-16 デュレクト コーポレイション Delivery system that is controlled by a high viscosity liquid
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5851229A (en) 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
EP0839525B1 (en) * 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2275422A1 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
DK0949905T3 (en) * 1996-12-20 2001-10-22 Alza Corp Injicertbart depotelpræparat and process for preparing
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JPH11158200A (en) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Human growth hormone/zinc complex and its use
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6039977A (en) * 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
WO1999033490A1 (en) 1997-12-26 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Sustained release medicinal compositions
DE19813010A1 (en) 1998-03-25 1999-10-14 Aventis Res & Tech Gmbh & Co Microcapsules with delayed release
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
AT251448T (en) 1998-12-23 2003-10-15 Amgen Inc Polyol / oil suspensions for verzörgerten release of proteins
AT248587T (en) 1999-06-14 2003-09-15 Baxter Int Microspheres sustained release
AU5025300A (en) * 1999-06-18 2001-01-09 Southern Biosystems, Inc. Compositions for controlled release of the hormone gnrh and its analogs
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
CA2406790C (en) 2000-04-19 2009-07-07 Genentech, Inc. Sustained release formulations
WO2002000261A2 (en) * 2000-06-26 2002-01-03 Monsanto Technology Llc Surfactant-containing formulations for extended release of somatotropin
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
GB2403086B (en) * 2003-06-17 2005-07-20 Motorola Inc Cartesian loop transmitter and method of adjusting an output level of such transmitter
AU2012238351B2 (en) * 2011-04-06 2016-11-24 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an HIV disease in humans

Also Published As

Publication number Publication date
EP1397155B1 (en) 2015-09-30
ES2554106T3 (en) 2015-12-16
WO2003000282A1 (en) 2003-01-03
US20030045454A1 (en) 2003-03-06
US7318931B2 (en) 2008-01-15
JP4460892B2 (en) 2010-05-12
JP2005508299A (en) 2005-03-31
US8067020B2 (en) 2011-11-29
DK1397155T3 (en) 2015-12-07
JP2010013456A (en) 2010-01-21
EP1397155A1 (en) 2004-03-17
CA2448218C (en) 2012-05-29
PT1397155E (en) 2015-12-07
US20080090754A1 (en) 2008-04-17
AU2002320122B2 (en) 2007-07-26
CA2448218A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
DE60230896D1 (en) Mikronadeltransportvorrichtung
DE60234189D1 (en) Selbst-formbare annuloplastie-ringprothese
DE60217162D1 (en) Tetrafluorethen-perfluorbutylethen-copolymer
DE60224810D1 (en) Radiotherapie-gerät
DE60235233D1 (en) Dicom-xml-generator
DE60213216D1 (en) Metalloproteinaseinhibitoren
DE50209614D1 (en) 2-heteroarylcarbonsäureamide
DE60235907D1 (en) Flächiges implantat
DE60229114D1 (en) Cathepsincystein-proteasehemmer
DE50204695D1 (en) Magnetresonanzkompatible metallische endoprothese
DE60217478D1 (en) Sychrongleichrichter
DE50213124D1 (en) Button-balloon-system
DE60236314D1 (en) Polyelektrolytzusammensetzungen
DE60226337D1 (en) Kerbschlagzähe polyharnstoffurethan-polysulfide
DE60135680D1 (en) Kolbenverdichter
DE60238039D1 (en) Polyurethanhartschaumstoffe
TWI322015B (en) Pharmaceutical formulation
DE60223590D1 (en) Reaktionsenergieaufnahmesystem
TWI347202B (en) Controlled release preparation
DE60225806D1 (en) Audiokanalübersetzung
DE60227094D1 (en) Microwell-biochip
GB2380760B (en) Retaining member
DE50211022D1 (en) Heteroarylcarbonsäureamide
EG24380A (en) Granule formulation
DE60112974D1 (en) Carbolinderivate

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed